Información de la revista
Vol. 113. Núm. 3.
Páginas T316-T318 (Marzo 2022)
Descargar PDF
Más opciones de artículo
Vol. 113. Núm. 3.
Páginas T316-T318 (Marzo 2022)
Case and Research Letter
Open Access
[Translated article] Effect of Cosmetic Camouflage in Adults With Vitiligo
Efecto del camuflaje cosmético en adultos con vitiligo
M.A. Morales-Sánchez
Autor para correspondencia

Corresponding author.
, J.P. Laguna-Meraz, M.L. Peralta-Pedrero, F. Jurado-Santa Cruz
Centro Dermatológico Dr. Ladislao de la Pascua, Secretaría de Salud de la Ciudad de México, Mexico City, Mexico
Contenido relaccionado
Actas Dermosifiliogr. 2022;113:316-810.1016/
M.A. Morales-Sánchez, J.P. Laguna-Meraz, M.L. Peralta-Pedrero, F. Jurado-Santa Cruz
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Descargar PDF
Figuras (1)
Texto completo
To the Editor:

Vitiligo is the most common acquired form of skin dyschromia and impacts the quality of life of affected individuals.1,2 Cosmetic camouflage is a therapeutic alternative that can be used to improve skin appearance and hence quality of life in patients with skin dyschromia.3 Several studies have demonstrated the effectiveness of this approach.4,5

An uncontrolled quasi-experimental study of patients with facial vitiligo treated at the Dr. Ladislao de la Pascua dermatology center, Mexico City, between July 2017 and May 2019, evaluated the impact of cosmetic camouflage on patient quality of life using generic and specific scales. The study was approved by relevant ethics and research committees and all study participants provided written informed consent. Adult vitiligo patients with spots in the facial region were recruited, regardless of the clinical variety and extent of the disease. Those with other concomitant dermatological diseases affecting the face, psychiatric diseases (depression and anxiety), and/or allergies to cosmetics were excluded.

Quality of life was assessed using disease-specific (vitiligo quality-of-life index [VitiQol]) and generic (Dermatology Life Quality Index [DLQI], EuroQol-5 Dimension [EQ5D], and the Short Form Health Survey [SF36]) scales at the initial visit (V1) and at weeks 8 (V2) and 16 (V3) of the study. Validated Mexican Spanish versions of all scales were used. For normally distributed data, a repeated measures analysis of variance (ANOVA) test was used to compare the scores of the quality-of-life questionnaires. In all other cases, the Friedman test was used. Statistical significance was set at P<0.05.

Participants were instructed how to use cosmetic camouflage in a workshop led by a professional makeup artist. The product used was Dermablend (Vichy Laboratories). The authors received no financial compensation for the use of this protocol and Vichy México was not involved in the study design or execution, or the statistical analysis. All participants were instructed to apply cosmetic camouflage for 16 weeks.

A total of 45 vitiligo patients with facial involvement were recruited. Of these, 42 completed 2 study visits and 38 completed the 3 scheduled visits. The sociodemographic variables of the study population are shown in Table 1. Significant changes in post- versus pre-intervention quality-of-life scores in the different questionnaires are shown in Table 2. In the DLQI questionnaire, a significant change in the effect of vitiligo on quality of life was observed for 27 (64.3%) patients: quality-of-life improvements were observed in 1 category for 18 (66.7%) patients, 2 categories for 6 (22.2%) patients, and 3 categories for 3 (11.1%) patients. These findings were similar to those of Ogenage et al.4 In our study, the use of cosmetic camouflage was associated with a positive change in quality of life that was evident within the first 8 weeks of intervention and, according to the results of the post hoc analysis, persisted until the end of the study (except for some categories of the SF36 questionnaire). These findings reflect a change that occurred shortly after beginning the intervention, as reported in similar studies in pediatric populations.6 The specific scale used to measure quality of life in our study was the ViTiQol score, for which significant differences were observed after versus before the intervention. Our study is the first to use this instrument to evaluate the effect of interventions in vitiligo patients and revealed a significant correlation (P<0.001) between the DLQI and ViTiQol questionnaire findings, in line with a previous validation study performed in a Mexican population.7

Table 1.

Characteristics of the Participants.

Variable n (%)
Male  10 (22.2%) 
Female  35 (77.8%) 
Age*  42.4±13.7 y 
Education level
No formal schooling  1 (2.2%) 
Lower  12 (26.7%) 
Medium  21 (46.7%) 
Higher  11 (24.4%) 
Worker  24 (53.3%) 
Non-worker  21 (46.7%) 

Mean and standard deviation.

Table 2.

Pre- Versus Post-Intervention Questionnaire Results.

  Before  After  P 
ViTiQola  46.2±22.7  31.9±20.4  <0.001 
DLQIb  8 (3.5-12)  3 (1-6.25)  <0.001 
EQ5D (visual analog scale)  82 (80-90)  90 (83-95)  0.007 
Emotional limitations  100 (33.3-100)  100 (100-100)  0.017 
Emotional well-being  68 (52-78)  76 (55-84)  0.011 
Social functioning  75 (62.5-100)  100 (75-100)  0.023 

Abbreviations: DLQI, Dermatology Life Quality Index; EQ5D, EuroQol-5 Dimension questionnaire; SF36, Short Form Health Survey; ViTiQol, Vitiligo Quality-Of-Life Index.


Analysis of variance.


Friedman test.

Analysis of the other study variables (sex, age, educational level, and occupation) revealed no significant differences that were maintained at the end of the study.

In conclusion, despite the study's limitations (including a predominantly female study population, the lack of a control group, and the absence of comparison with another intervention to improve quality of life), our findings demonstrate an improvement in quality of life in vitiligo patients who used cosmetic camouflage (Fig. 1). This intervention proved to be fast and safe, with adequate adherence and good patient satisfaction, and therefore represents a valid option as a therapeutic supplement for vitiligo.

Figure 1.

Patient without (A) and with (B) camouflage makeup.


Dermablend products were donated by Vichy México. The authors did not receive any financial compensation for the study protocol used. Vichy México was not involved in the study design or execution, or in the statistical analysis.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

K. Ezzedine, V. Eleftheriadou, M. Whitton, N. van Geel.
W. Me, A. Dm, B.U.G. Cw.
Interventions for vitiligo.
Cochrane Library, (2015), pp. 1-48
L.L. Levy, J.J. Emer.
Emotional benefit of cosmetic camouflage in the treatment of facial skin conditions: personal experience and review.
Clin Cosmet Investig Dermatol, 5 (2012), pp. 173-182
K. Ongenae, L. Dierckxsens, L. Brochez, N. Van Geel, J.M. Naeyaert.
Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage.
Dermatology, 210 (2005), pp. 279-285
M. Tanioka, Y. Yamamoto, M. Kato, Y. Miyachi.
Camouflage for patients with vitiligo vulgaris improved their quality of life.
J Cosmet Dermatol, 9 (2010), pp. 72-75
S.D. Cadmus, A.D. Lundgren, A.M. Ahmed.
Therapeutic interventions to lessen the psychosocial effect of vitiligo in children: a review.
Pediatr Dermatol, 35 (2018), pp. 441-447
M.A. Morales-Sánchez, M. Vargas-Salinas, M.L. Peralta-Pedrero, M.G. Olguín- García, F. Jurado-Santa Cruz.
Impact of vitiligo on quality of life.
Actas Dermosifiliogr, 108 (2017), pp. 637-642
Copyright © 2021. AEDV
Actas Dermo-Sifiliográficas
Opciones de artículo
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?